New biologic clears psoriasis in 42 percent of patients

| Melissa Leavitt

A new biologic medication for psoriasis scored positive results in a Phase III clinical trial.

Patients taking brodalumab experienced significant skin improvement after three months on the drug, according to a statement released by the drug's manufacturer. The placebo-controlled trial, which involved 661 participants, evaluated the safety and effectiveness of taking 210-milligram and 140-milligram doses to treat psoriasis.

At the end of 12 weeks, more than 83 percent of patients taking the 210-milligram (mg) dose experienced a 75 percent reduction in psoriasis severity, with almost 42 percent experiencing complete clearing.

Of the patients who took the 140-mg dose, approximately 60 percent experienced a 75 percent reduction in severity. Approximately 23 percent of patients in this group experienced complete skin clearing.

"When we look at these results, we see a very profound level of response," said Dr. Kim Papp, the coordinating investigator for the trial.

The trial will extend for five years to explore the long-term efficacy of the drug, Papp said. "That will tell us how well this effect will stand up over the years."

Amgen and AstraZeneca, the makers of brodalumab, reported that 1.8 percent of patients in the 210-mg group and 2.7 percent of patients in the 140-mg group experienced serious side effects. The statement did not specify what these serious side effects were, although it listed colds, headaches and upper respiratory tract infections as the most common side effects.

Unlike other drugs on the market, brodalumab targets interleukin-17 (IL-17), a protein, or cytokine, that triggers inflammatory response. Biologics that are currently available target other cytokines.

IL-17 is one of the key drivers of inflammation in psoriasis. Brodalumab, delivered by injection, binds to the IL-17 receptor, which blocks the receptor from receiving the signals that promote inflammation.

Phase III trials comparing brodalumab with Stelara (ustekinumab), a biologic drug targeting IL-12 and IL-23, for the treatment of psoriasis are ongoing. In addition, a Phase III trial testing brodalumab for psoriatic arthritis is currently recruiting.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Easy on the joints and mentally soothing, aquatic exercises offer many benefits...
Innovations in drug therapy have changed the landscape since these individuals...
Andrew Blauvelt, M.D., MBA, sheds light on the importance of clinical trials...
With help from his old bike and a biologic, Barry Bonner overcomes PsA and...
Rheumatologists and dermatologists join forces to defeat a common enemy.
Psoriasis updates from the 76th annual meeting of the American Academy of...
Culinary enthusiasts offer grade-A tips for taking the aches and pains out of...
For some psoriasis patients, getting the right diagnosis isn’t always so black...
NPF launches a clearinghouse for clinical trial info, including how to find one...